When do the LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE patents expire, and when will generic LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	208475-001	Sep 8, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Empi	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE	epinephrine; lidocaine hydrochloride	SOLUTION;IONTOPHORESIS, TOPICAL	021486-001	Oct 26, 2004		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	089649-001	Jun 21, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 13, 2026

Lidocaine hydrochloride and epinephrine is an established, low-cycle-time injectable local anesthetic used across emergency, peri-procedural, and outpatient settings. The investment profile is driven by (1) supply-chain resiliency in sterile injectables, (2) near-to-mid-term generic replacement risk tied to facility-level controllability and paragraph IV/ANDA momentum, and (3) payer pressure and ASP compression rather than meaningful patent exclusivity expansion. The drug’s economic fundamentals typically hinge on volume retention, contract pharmacy share, wholesaler buy-rates, and product line breadth (multiple strengths, multiple package sizes, single-dose vs multi-dose formats) more than on clinical differentiation.

No patent estate or FDA Orange Book status can be mapped for this specific combination product from the information provided, so this report does not cite specific protection terms, expiration dates, or listed FDA reference products.

What is lidocaine hydrochloride and epinephrine used for in the US and why does it matter to revenue?

Direct answer: The combination is used to provide local anesthesia with vasoconstriction (epinephrine) to prolong effect, reduce systemic absorption, and improve hemostasis in selected procedures. Revenue is tied to procedure volumes and the breadth of settings that routinely stock injectable local anesthetics.

Common clinical and procedural use cases

Cutaneous and mucosal local anesthesia for minor procedures and laceration repair
Dental procedures, including local infiltration and nerve blocks
Dermatologic and outpatient minor surgery workflows where hemostasis and longer duration are desired
Emergency department and urgent care workflows using prefilled or cart-stable sterile injections (product availability and packaging matter)

Commercial implications for investors

Purchase is often protocol-driven and contract-driven, not physician choice-driven once a generic becomes established.
Inventory stocking decisions favor reliable supply, predictable delivery, and minimal shortages.
Product line breadth (strength combinations, vial sizes, prefilled formats where applicable) improves formulary stickiness.

What drives pricing and ASP trends for lidocaine with epinephrine in injectable local anesthetics?

Direct answer: Pricing is primarily a function of generic competition, payer reimbursement, and manufacturing cost inflation in sterile injectables. Epinephrine inclusion tends to stabilize differentiation at the molecule level, but not enough to prevent strong ASP compression once multiple ANDAs enter.

Key pricing levers

Wholesale acquisition cost declines after generic entrants and PBM contracting
Contract procurement favors lowest total landed cost plus service level
Sterile manufacturing costs are a major swing factor: fill-finish capacity, aseptic controls, and quality remediation can move cost curves quickly

Margin structure investors should underwrite

Gross margin sensitivity to sterile fill-finish utilization and batch yield
Working-capital pressure from inventory build during shortages, then rapid drawdowns post-normalization
Channel fill strategy: hospital group purchasing vs distributor allocations

How many competitors typically supply lidocaine hydrochloride and epinephrine injectable in the US?

Direct answer: The market structure is usually fragmented: multiple ANDA suppliers across strengths and package sizes. Competition is driven by licensing, fill-finish scale, and quality record more than by patents.

Competitive dimensions that decide share

Supply reliability and shortage history
Lot consistency, sterility assurance, and customer service for large accounts
Availability of commonly used package sizes for hospital formularies

What patents protect lidocaine hydrochloride and epinephrine, and what coverage gaps exist?

Direct answer: This report cannot assign specific patent numbers, listed FDA Orange Book protections, or enforceable expiration dates for the exact drug combination from the provided input. Patent coverage for such established injectables often exists as a patchwork across formulation, manufacturing process, and packaging, with many claims expiring earlier than current commercial value.

Where protection typically concentrates for old injectables

Sterile manufacturing process claims (aseptic method parameters, critical quality attributes)
Specific concentration/ratio formulations or preservative/antioxidant systems
Container closure systems, tamper-evidence, or device-integrated delivery systems

Investment implication of “coverage patchwork” structures

Even when some patents remain, they may be narrow or easier to design around at manufacturing level.
The decisive investor question is not “is there any patent,” but “are remaining patents operationally enforceable against generic ANDA design choices.” This cannot be determined from the provided information.

When does lidocaine hydrochloride and epinephrine lose exclusivity, and what timing risks matter?

Direct answer: Exclusivity and patent-loss timelines depend on the FDA-listed reference product and its Orange Book entries. Those data are not provided, so this report does not map any exclusivity cliff.

Timing risks investors should model for sterile injectables

ANDA approval timelines relative to market penetration
Supply constraints that can delay generic substitution
Court or settlement timing that can hold up or accelerate generic entry

What paragraph IV or ANDA challenges are associated with lidocaine hydrochloride and epinephrine?

Direct answer: No specific Paragraph IV notices, ANDA case numbers, or district court outcomes are provided, so this report cannot identify active challenges or settlement terms.

How to interpret generic-entry risk when litigation data is absent

For established injectables, generic substitution typically occurs once approvals and supply readiness align.
Litigation can create short-term delays, but pricing trends in mature generics usually track approvals and capacity additions more than injunction outcomes.

What is the Orange Book status of lidocaine hydrochloride and epinephrine injectable?

Direct answer: Orange Book status cannot be validated from the provided input.

What investors should normally check in the Orange Book (method)

Whether the drug is listed as a reference listed drug (RLD)
Patent type (drug substance, drug product, formulation, method-of-use)
Expiration dates, statutory exclusivity, and whether patents are “listed” versus “blocking”

This report cannot execute the mapping without the FDA RLD identifier and the Orange Book list for the specific strength and dosage form.

How strong is the patent estate for this product class, and what does “narrow claims” mean for generic economics?

Direct answer: For mature local anesthetic combinations, patent estates tend to be either expired or narrow enough that generic economics depend more on manufacturing and procurement than on patent barriers. This report does not quantify claim strength because no patent set is provided.

Practical assessment framework

Narrow manufacturing/process claims generally shift risk to validation and regulatory burden, not to long-term market lock
If any protection remains, it is often about specific fill-finish conditions or container closure features that can be engineered around
Investor value is concentrated in supply execution and quality record, not in long residual exclusivity

What formulations and package strengths affect exclusivity and switching?

Direct answer: Lidocaine hydrochloride and epinephrine products vary by concentration and package size. Switching risk is greatest where multiple ANDAs offer interchangeable strengths and packaging suitable for hospital workflows.

Form-factor issues that change economics

Vial size (e.g., multi-dose vs single-use)
Labeling and compatibility with common hospital systems
Stability and cold-chain requirements if any (depends on exact formulation)

This report does not identify which strengths are marketed because product-specific labeling and FDA listings are not provided.

What manufacturing/IP barriers exist for injectable lidocaine with epinephrine?

Direct answer: The principal barriers are sterile manufacturing controls and quality systems, with epinephrine increasing formulation sensitivity due to stability and potential assay variability. This report cannot map specific manufacturing patents or exclusive know-how tied to the exact combination.

Execution barriers that affect investor confidence

Aseptic processing robustness and contamination control
Batch-to-batch potency uniformity and epinephrine stability management
Supplier qualification for critical starting materials
Regulatory inspection history and corrective action timelines

How does lidocaine with epinephrine compare with lidocaine alone or other local anesthetic systems for market competitiveness?

Direct answer: Lidocaine alone competes as an alternative local anesthetic, but epinephrine adds prolonged effect and hemostasis utility in many procedural contexts. Clinically, this supports use-case retention, but commercial substitution still occurs when generics and formulary contracts dominate.

Competitive alternatives

Lidocaine hydrochloride alone (shorter duration without vasoconstriction)
Other local anesthetic mixes (e.g., lidocaine with different vasoconstrictors or alternative anesthetic agents)
Topical anesthetic systems for superficial procedures (separate channel economics)

This comparison cannot be tied to product-specific market share without additional commercial data.

What regulatory factors affect supply continuity and patient access?

Direct answer: Sterile injectable local anesthetics are regulated under standard FDA frameworks for ANDAs, with added risk concentration around manufacturing quality, sterility assurance, and labeling compliance.

Investor-sensitive regulatory scenarios

FDA warning letters or inspection outcomes at sterile sites
Remediation timelines affecting launch dates and volume
Lot releases and recalls impacting customer retention

Commercial scenario planning: base case, upside, and downside for an investor in this category

Direct answer: The category’s investment outcome is typically capacity-driven and contract-driven. The upside case comes from supply reliability plus multi-strength portfolio expansion. The downside case comes from sterile manufacturing disruptions, batch yield problems, or accelerated generic substitution that compresses ASP faster than cost declines.

Base case (typical mature injectable profile)

ASP continues to soften modestly with incremental entrants
Volume growth is limited, controlled by group purchasing and hospital tender cycles
Margin stability improves only if manufacturing utilization and yield remain high

Upside case (execution-led)

Stable fill-finish capacity reduces lost sales during shortages
Portfolio expansion across package sizes locks formularies
Quality performance reduces recall risk and improves customer retention

Downside case (supply and pricing)

Sterile manufacturing disruption triggers lost contract volume
Higher cost base from remediation or quality actions outpaces ASP decline
Share shifts to lower-cost competitors if supply continuity deteriorates

Revenue exposure model: where demand is most resilient and where it is most elastic

Direct answer: Resilient demand sits in routine minor procedures and emergency settings where clinicians follow protocols and hospitals maintain stock. Elasticity rises when payers shift procurement to lowest-cost equivalents and when multiple ANDAs exist in the same strength/package tier.

Elasticity drivers

Formularies and group purchasing incentives
Substitution policies in hospital pharmacy departments
Tender cycles that favor lowest total cost

Key diligence checklist for an investment or licensing decision in this drug class

Direct answer: For sterile injectables like lidocaine with epinephrine, diligence centers on supply, regulatory history, and customer contracting rather than on long exclusivity.

Supplier and manufacturing

Sterile site capacity, fill-finish throughput, and redundancy
Batch yield trends and deviation rates
CAPA history and inspection remediation milestones

Product/portfolio

Full strength and package coverage aligned to hospital purchasing catalogs
Labeling compatibility and shelf-life performance in distribution

Commercial

Contract coverage with hospital systems and GPOs
Channel mix (direct vs distributor) and buy-rate stability
Recall and shortage history in customers’ procurement decisions

IP and regulatory

Confirm FDA reference product and Orange Book listings for the specific strength
Map any remaining patents to specific ANDA design-around feasibility
Review patent litigation history tied to the RLD (if any)

Key Takeaways

Lidocaine hydrochloride and epinephrine is a mature injectable local anesthetic where investment returns are typically driven by supply reliability, sterile manufacturing execution, and procurement contracting.
Commercial differentiation is limited once multiple ANDA suppliers exist; ASP pressure usually dominates over clinical differentiation.
Patent and Orange Book-driven exclusivity timelines cannot be mapped from the provided input, so do not underwrite an exclusivity-driven thesis without verifying the exact FDA reference listed drug and its listed patents.
The highest-risk variables for value capture are sterile site disruptions, quality remediation timelines, and accelerated generic substitution into common strength/package configurations.
The highest-probability value creation levers are portfolio coverage, manufacturing resilience, and minimizing lost sales during capacity constraints.

FAQs

1) Does lidocaine hydrochloride and epinephrine face significant long-term patent exclusivity risk like other mature generics?
In most mature injectable anesthetic classes, exclusivity is often short-lived or fragmented; generic economics tend to dominate after ANDA entry. This requires validation of the exact FDA-listed RLD and its Orange Book patents.

2) Are hospital purchasing decisions more influenced by clinical preference or contracting?
Hospital pharmacy selection in sterile injectables is typically driven by GPO contracts, tender pricing, and supply reliability.

3) What manufacturing quality factors most affect profitability for sterile injectables?
Aseptic process consistency, batch yield, deviation rate, sterility assurance, and remediation timelines after inspections or quality events.

4) What should be the primary indicator for near-term generic substitution?
For mature injectables, it is approval activity plus evidence of supply readiness across multiple strengths and package sizes, not only patent timelines.

5) Is the epinephrine component an engineering or stability concern for generic manufacturers?
It can be formulation-sensitive; investors should diligence stability-indicating assay controls, potency uniformity, and validated manufacturing controls for the exact generic design.

References

No sources are provided in the prompt, and no FDA Orange Book, patent, or litigation identifiers for the exact strength/dosage form were supplied.

US Patents:	0
Applicants:	6
NDAs:	14

AI Deep Research

Questions you can ask:

Summary for LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE